FDA Advisory Panel Votes to Loosen Rules on BPC-157, TB-500, and MOTS-C Despite Agency Scientists’ Opposition

An FDA advisory panel voted 8-6 on July 23, 2026, to allow compounding of BPC-157, TB-500, and MOTS-C despite agency scientists’ objections. Here is what the vote means and what consumers should know.